Bangladesh should engage the private sector for malaria elimination by 2030 - McArdle, Ryan Patrick; Phru, Ching Swe; Hossain, Mohammad Sharif; Alam, Mohammad Shafiul; Haldar, Kasturi (medRxiv, 2024)
Bangladesh reduced malaria by 93% from 2008-2020 through the action of governmental and non-governmental organizations, yet ∼18 million people continue to live at risk of infection. For-profit private healthcare providers, catalytic for malaria elimination in many countries, have not yet been integrated into the national program. By imposing strict definitions on a large and complex literature surrounding private healthcare sector engagement, we distilled eight distinct strategies important in other developing settings: contracting, financing, subsidization, regulation, social franchising, demand-side interventions, infrastructure-building and training. We weighed these in the context of Bangladesh’s flourishing private health care sector—driven by patient demand, self-interest, and aspirations for public good—as well as the heterogeneity in provider capacity and malaria prevalence across districts. We developed a new model dependent on five strategies of subsidization, training, infrastructure building, demand-side intervention, and referral financing, to empower Bangladesh’s phased agenda of eliminating indigenous malaria transmission by 2030.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors